Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3

Journal of Hepatology

Volumn 59, Issue 1, 2013, Pages 31-37

  Silva, Marcelo O ^a   Treitel, Michelle ^b   Graham, Donald J ^b   Curry, Stephanie ^b   Frontera, Maria J ^a   McMonagle, Patricia ^b   Gupta, Samir ^b   Hughes, Eric ^b   Chase, Robert ^b   Lahser, Fred ^b   Barnard, Richard J O ^b   Howe, Anita Y M ^b   Howe, John A ^b  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Efficacy; Genotype 2; Genotype 3; Hepatitis C virus

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PLACEBO; TELAPREVIR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ASSESSMENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENOTYPE; HEART ATRIUM FIBRILLATION; HEPATITIS C; HUMAN; IC 50; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCULOSKELETAL PAIN; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPLICON; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KINETICS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; REPLICON; RNA, VIRAL; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84879159643     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.02.018     Document Type: Article

References (19)

1. O. Dalgard, K. Bjoro, H. Ring-Larsen, E. Bjornsson, M. Holberg-Petersen, and E. Skovlund Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response Hepatology 47 2008 35 42
2. A. Mangia, R. Santoro, N. Minerva, G.L. Ricci, V. Carretta, and M. Persico Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 N Engl J Med 352 2005 2609 2617
3. M.L. Shiffman, F. Suter, B.R. Bacon, D. Nelson, H. Harley, and R. Sola Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357 2007 124 134
4. B. Willems, S.J. Hadziyannis, T.R. Morgan, M. Diago, P. Marcellin, and D. Bernstein Should treatment with peginterferon plus ribarvirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? J Hepatol 46 2007 S6
5. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
6. B. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
7. F. Poordad, J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
8. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
9. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, R.K. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
10. S.S. Taremi, B. Beyer, M. Maher, N. Yao, W. Prosise, and P.C. Weber Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease Protein Sci 7 1998 2143 2149
11. R. Zhang, B.M. Beyer, J. Durkin, R. Ingram, F.G. Njoroge, and W.T. Windsor A continuous spectrophotometric assay for the hepatitis C virus serine protease Anal Biochem 270 1999 268 275
12. B.A. Malcolm, R. Liu, F. Lahser, S. Agrawal, B. Belanger, and N. Butkiewicz SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob Agents Chemother 50 2006 1013 1020
13. R. Chase, A. Skelton, E. Xia, S. Curry, S. Liu, and P. McMonagle A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors Antiviral Res 84 2009 178 184
14. S.W. Ludmerer, D.J. Graham, M. Patel, K. Gilbert, M. Stahlhut, and D.B. Olsen A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV J Virol Methods 151 2008 301 307
15. X. Tong, S. Bogen, R. Chase, V. Girijavallabhan, Z. Guo, and F.G. Njoroge Characterization of resistance mutations against HCV ketoamide protease inhibitors Antiviral Res 77 2008 177 185
16. G.R. Foster, C. Hezode, J.P. Bronowicki, G. Carosi, O. Weiland, and L. Verlinden Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections Gastroenterology 141 2011 881 889
17. J.M. Gottwein, T.K. Scheel, T.B. Jensen, L. Ghanem, and J. Bukh Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses Gastroenterology 141 2011 1067 1079
18. C. Sarrazin, R. Rouzier, F. Wagner, N. Forestier, D. Larrey, and S.K. Gupta SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha 2b for genotype 1 nonresponders Gastroenterology 132 2007 1270 1278
19. J. de Bruijne, J.F. Bergmann, H.W. Reesink, C.J. Weegink, R. Molenkamp, and J. Schinkel Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients Hepatology 52 2010 1590 1599